Key Takeaways:
- Grayscale filed amendment no. 4 to its S-3 for a spot Zcash ETF on NYSE Arca.
- ZEC rose 2% to $510.70 as traders weighed the filing and Ironwood upgrade.
- DCG unit may contribute 200,000 ZEC tokens under a non-binding arrangement.
Key Takeaways:

ZEC climbed 2% to $510.70 after Grayscale filed amendment no. 4 to its S-3 registration for a spot Zcash ETF on NYSE Arca.
The amendment, submitted to the US Securities and Exchange Commission, advances the conversion of the Grayscale Zcash Trust into a spot exchange-traded fund, according to the registration statement. Grayscale plans to list shares under the ticker ZCSH and has not disclosed a management fee or waiver for what would be the first spot ETF tracking a privacy coin.
A notable change from the prior filing concerns share creation and redemption. The Grayscale Zcash ETF will process creations and redemptions primarily through cash orders, with in-kind creation still available but in-kind redemptions no longer permitted. The filing also shows the sponsor is in discussions with DCG International Investments Ltd, a wholly owned indirect subsidiary of parent Digital Currency Group, over a potential contribution of 200,000 ZEC tokens in exchange for shares through an authorized participant. Those talks are non-binding.
ZEC traded between $500.47 and $514.03 over the past 24 hours, with volume down 16% despite the filing. The token holds above its 50-day simple moving average, with analysts pegging $520 as local resistance after the Ironwood upgrade and $550 as the next major hurdle. CoinGlass data showed mixed derivatives positioning: total ZEC futures open interest rose 1%, with open interest on Binance down 3.90% on profit-taking while climbing almost 9% on Hyperliquid, 3.40% on OKX and 2.18% on KuCoin.
If approved, a spot Zcash ETF would give institutional investors regulated exposure to ZEC, potentially deepening liquidity and supporting further price gains. The filing also extends the crypto ETF wave into privacy-focused assets, a category regulators have historically treated with caution. SEC review and NYSE Arca listing procedures remain pending, with no timeline disclosed.
This article is for informational purposes only and does not constitute investment advice.